Verificando…
Traducido automáticamente. Dosis y advertencias: consulta el original en inglés. Leer en inglés

Zorgesic

NAFDAC Reg. No. A11-101107 Estupefaciente

Registrado en NAFDAC. Registro activoAs of 15 November 2026 · synced automatically from official sources.
Producto
Zorgesic
Número NAFDAC
A11-101107
Principio activo
Orphenadrine Citrate; Paracetamol
Dosis
500 mg; 35 mg
Forma
Tablet
Tamaño del envase
10 x 10's
Fabricante
No Constan
Solicitante (titular)
Zolon Healthcare Limited
Approved
24 Feb 2026
Estado
Activo Ver en NAFDAC ↗
Registro válido hasta
23 Feb 2031
Alertas de la OMS
No se ha encontrado ninguno
Informes de la comunidad
Ninguno
Tiempos comprobados
0

Pero sobre el medicamento, Paracetamol: uses, dosage and brands worldwide

Lo que encontramos

  • Zorgesic is on the NAFDAC register with an active registration (A11-101107). A valid number alone does not prove a pack is genuine — counterfeiters copy real numbers, so also check the expiry date, seal and print quality.

Generado automáticamente a partir del registro NAFDAC, QUIÉN alerta y los datos de la comunidad a partir de hoy. Este no es un consejo médico. Siga siempre a su médico o farmacéutico.

How to use Zorgesic

Lo que dice el prospecto oficial. Si te lo recetó un médico, sigue la receta. Si el prospecto de tu caja es distinto, manda el de tu caja.

Para quién es

Orphenadrine citrate extended-release tablets are indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute painful musculoskeletal conditions.

Cómo tomarlo y con qué frecuencia

Adults Two tablets per day; one in the morning and one in the evening.

Infancia
  • Safety and effectiveness
  • In pediatric patients have not been established
Talk to a doctor first if
  • Orphenadrine citrate extended-release tablets are contraindicated in patients with glaucoma, pyloric or duodenal obstruction, stenosing peptic ulcers, prostatic hypertrophy or obstruction of the bladder neck, cardio-spasm (mega-esophagus) and myasthenia gravis
  • Orphenadrine citrate tablets are contraindicated in patients who have demonstrated a previous hypersensitivity to the drug
Warnings

Some patients may experience transient episodes of light-headedness, dizziness or syncope. Orphenadrine may impair the ability of the patient to engage in potentially hazardous activities such as operating machinery or driving a motor vehicle; ambulatory patients should therefore be cautioned accordingly.

Posibles efectos secundarios

Adverse reactions of orphenadrine are mainly due to the mild anticholinergic action of orphenadrine, and are usually associated with higher dosage. Dryness of the mouth is usually the first adverse effect to appear. When the daily dose is increased, possible adverse effects include: tachycardia, palpitation, urinary hesitancy or retention, blurred vision, dilatation of pupils, increased ocular tension, weakness, nausea, vomiting, headache, dizziness, constipation, drowsiness, hypersensitivity reactions, pruritus, hallucinations, agitation, tremor, gastric irritation, and rarely urticaria and other dermatoses. Infrequently, an elderly patient may experience some degree of mental confusion. …

Pregnancy and breastfeeding

Pregnancy Pregnancy Category C Animal reproduction studies have not been conducted with orphenadrine. It is also not known whether orphenadrine can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Orphenadrine should be given to a pregnant woman only if clearly needed.

If you take too much

Orphenadrine is toxic when overdosed and typically induces anticholinergic effects. In a review of orphenadrine toxicity, the minimum lethal dose was found to be 2 to 3 grams for adults; however, the range of toxicity is variable and unpredictable. Treatment for orphenadrine overdose is evacuation of stomach contents (when necessary), charcoal at repeated doses, intensive monitoring, and appropriate supportive treatment of any emergent anticholinergic effects.

Dependencia y abuso

Orphenadrine has been chronically abused for its euphoric effects. The mood elevating effects may occur at therapeutic doses of orphenadrine.

Si olvidas una dosis

Tómala en cuanto te acuerdes, salvo que falte poco para la siguiente. En ese caso, sáltate la olvidada. Nunca tomes dos dosis a la vez para compensar. Revisa tu prospecto, porque algunos medicamentos son distintos.

From the official U.S. FDA label for this active ingredient. Your pack may have a different strength, so always read its leaflet. If a doctor prescribed it, follow the prescription. Ask a pharmacist if you are unsure. Label dated 2026-01-01.

Label for orphenadrine citrate and paracetamol, the active ingredient registered with NAFDAC.

Check your pack of Zorgesic

Add the expiry date on your pack for a full Trust Score.

O haz fotos de la caja
Te quedan 3 verificaciones gratis hoy Official sources: U.S. FDA · EMA (EU) · Health Canada · WHO alerts

About Zorgesic

What is in Zorgesic?

Zorgesic contains Orphenadrine Citrate; Paracetamol (500 mg; 35 mg), as tablet, according to its NAFDAC registration record.

Is Zorgesic registered with NAFDAC?

Yes. Zorgesic is listed on the NAFDAC register under registration number A11-101107, and its registration is active as of 15 November 2026.

Has Zorgesic been flagged as fake or recalled?

No WHO falsified or substandard medical product alert currently matches Zorgesic in our automatically synced alert list.

How can I check that my pack of Zorgesic is genuine?

Run a free authenticity scan with the NAFDAC number A11-101107, your pack's expiry date and batch number to get a Trust Score, compare the pack with the NAFDAC record (ingredient, strength, form, manufacturer), and buy only from licensed pharmacies.

How do I take Zorgesic?

Follow your prescription or the leaflet in your pack. The official label says: Adults Two tablets per day; one in the morning and one in the evening.…

What is Zorgesic used for?

Orphenadrine citrate extended-release tablets are indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute painful musculoskeletal conditions. (Summarised from the official U.S. FDA label for orphenadrine citrate and paracetamol. Always follow your doctor or pharmacist.)

Patient reviews

–No reviews yet
5★
0
4★
0
3★
0
2★
0
1★
0
Have you used Zorgesic? Share your experience to help other patients. Sign in to review

Reviews are personal experiences from PillVera users, not medical advice. Report side effects to your doctor and to NAFDAC.